Abstract
Objectives
We aimed to evaluate the side effects seen in adolescents with clozapine use followed up in an inpatient clinic and the approaches to the treatment of side effects in a naturalistic pattern.
Materials and Methods
Sociodemographic data, International Statistical Classification of Diseases and Related Health Problems-10 diagnosis, side effects, management and outcomes, prophylactic treatments for side effects, time to initiation of clozapine and clinical observation scores were recorded.
Results
The most commonly reported side effects were extrapyramidal system side effects (n=91, 62.8%), followed by sialorrhea (n=57, 39.3%), fasciculation (n=55, 37.9%), sedation (n=43, 29.7%) and constipation (n=40, 27.4%). Of the serious side effects, seizures occurred in 5 patients (3.4%), neutropenia occurred in 5 patients (3.5%); ileus and myocarditis were not observed. The mean clozapine discharge dose was 323.9 (±124.45) mg/g. The mean number of antipsychotics used before clozapine was 3, and the mean duration from the first treatment initiation, due to a serious psychiatric diagnosis (schizophrenia, bipolar disorder), to clozapine initiation was 18.4 (±24) weeks. Valproic acid was initiated in 108 patients (74%) and topiramate in 4 patients (2.7%) for seizure prophylaxis, as seizures are one of the serious side effects of clozapine. Five patients (3.5%) developed neutropenia. The most common reason for discontinuation of clozapine treatment was non-compliance (n=8, 14%), while five patients (9.4%) were discontinued due to serious side effects or risk of these side effects.
Conclusion
In the adolescent population, it is possible to effectively intervene with different options for side effects that may affect treatment adherence due to clozapine treatment; thus preventing discontinuation of treatment and contributing to improving prognosis by reducing the time without effective symptomatic improvement.
Keywords: Clozapine, schizophrenia, bipolar
References
Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:1-5.
Gurrera RJ, Gearin PF, Love J, Li KJ, Xu A, Donaghey FH, Gerace MR. Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis. Acta Psychiatr Scand. 2022;145:423-441.
Adnan M, Motiwala F, Trivedi C, Sultana T, Mansuri Z, Jain S. Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2022;32:2-11.
Tungaraza TE, Ahmed W, Chira C, Turner E, Mayaki S, Nandhra HS, Edwards T, Farooq S. Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams. Ther Adv Psychopharmacol. 2017;7:103-111.
Pattnaik JI, Panda UK, Chandran S, Padhy S, Ravan JR. Treatment resistant psychosis in children and adolescents and clozapine: nuances. Front Psychiatry. 2023;14:1014540.
Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Coma Fusté A, Furu K, Garuoliené K, Hoffmann F, Hollingworth S, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Piovani D, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Siskind D, Skurtveit S, Verdoux H, Wang LJ, Zara Yahni C, Zoëga H, Taylor D. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136:37-51.
Rachamallu V, Elberson BW, Vutam E, Aligeti M. Off-label use of clozapine in children and adolescents-a literature review. Am J Ther. 2019;26:e406-e416.
Li XH, Zhong XM, Lu L, Zheng W, Wang SB, Rao WW, Wang S, Ng CH, Ungvari GS, Wang G, Xiang YT. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2020;50:583-594.
Maher KN, Tan M, Tossell JW, Weisinger B, Gochman P, Miller R, Greenstein D, Overman GP, Rapoport JL, Gogtay N. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2013;23:110-116.
Steinauer LM, Leung JG, Burkey BW, McGrane IR, Letts V, Goren JL, Hoeft DM, Mullen S, Maroney M, Schak KM, Vande Voort JL. A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization. J Child Adolesc Psychopharmacol. 2018;28:615-619.
Yalcin O, Kaymak G, Erdogan A, Tanidir C, Karacetin G, Kilicoglu AG, Mutlu C, Adaletli H, Gunes H, Bahali K, Ayik B, Uneri OS. A retrospective investigation of clozapine treatment in autistic and nonautistic children and adolescents in an inpatient clinic in Turkey. J Child Adolesc Psychopharmacol. 2016;26:815-821.
Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013;74:20799.
Sagreiya H, Chen YR, Kumarasamy NA, Ponnusamy K, Chen D, Das AK. Differences in antipsychotic-related adverse events in adult, pediatric, and geriatric populations. Cureus. 2017;9:e1059.
Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry. 2013;26:219-230.
Guy W. Clinical global impressions scale. Psychiatry. 1976.
Meyer JM, Stahl SM. The clozapine handbook: Stahl’s handbooks. Cambridge University Press; 2019.
Mozes T, Toren P, Chernauzan N, Mester R, Yoran-Hegesh R, Blumensohn R, Weizman A. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33:65-70.
Kranzler HN, Cohen SD. Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. Child Adolesc Psychiatr Clin N Am. 2013;22:727-744.
Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Coma Fusté A, Furu K, Garuoliené K, Hoffmann F, Hollingworth S, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Piovani D, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Siskind D, Skurtveit S, Verdoux H, Wang LJ, Zara Yahni C, Zoëga H, Taylor D. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136:37-51.
Trinczek E, Heinzel-Gutenbrunner M, Haberhausen M, Bachmann CJ. Time to initiation of clozapine treatment in children and adolescents with early-onset schizophrenia. Pharmacopsychiatry. 2016;49:254-259.
Schneider C, Papachristou E, Wimberley T, Gasse C, Dima D, MacCabe JH, Mortensen PB, Frangou S. Clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. Eur Neuropsychopharmacol. 2015;25:857-863.
Pagsberg AK, Melau M. Current treatment options in early-onset psychosis. Adolescent Psychosis. 1st ed. Academic Press; 2023:273-298.
de Filippis R, Gaetano R, Schoretsanitis G, Verde G, Oliveti CA, Kane JM, Segura-Garcia C, De Fazio P. Clozapine management in schizophrenia inpatients: a 5-year prospective observational study of its safety and tolerability profile. Neuropsychiatr Dis Treat. 2021;17:2141-2150.
Mukherjee H, Sazhin V. Predictors of functioning and clinical outcomes in inpatient with schizophrenia on clozapine augmented with antipsychotics. Australasian Psychiatry. 2022;30:100-104.
Boland X, Dratcu L. First use of clozapine point of care testing in acute inpatient psychiatry: preliminary report. J Psychiatr Pract. 2022;28:62-66.
Komaryk A, Elbe D, Burgess L. Retrospective Review of clozapine use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2021;30:36-48.
Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80:18com12123.
Kasoff LI, Ahn K, Gochman P, Broadnax DD, Rapoport JL. Strong treatment response and high maintenance rates of clozapine in childhood-onset schizophrenia. Child Adolesc Psychopharmacol. 2016;26:428-435.
Peluso MJ, Lewis SW, Barnes TRE, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2018;200:387-392.
Takeuchi H, Borlido C, Sanches M, Teo C, Harber L, Agid O, Remington G. Adherence to clozapine vs. other antipsychotics in schizophrenia. Acta Psychiatr Scand. 2020;142:87-95.
Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 2015;132:231-240.
Bobb VT, Jarskog LF, Coffey BJ. Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine. J Child Adolesc Psychopharmacol. 2010;20:539-543.
Branik E, Nitschke M. Pericarditis and polyserositis as a side effect of clozapine in an adolescent girl. J Child Adolesc Psychopharmacol. 2004;14:311-314.
Chow V, Feijo I, Trieu J, Starling J, Kritharides L. Successful rechallenge of clozapine therapy following previous clozapine-induced myocarditis confirmed on cardiac MRI. J Child Adolesc Psychopharmacol. 2014;24:99-101.
Bellissima BL, Tingle MD, Cicović A, Alawami M, Kenedi C. A systematic review of clozapine-induced myocarditis. Int J Cardiol. 2018;259:122-129. Erratum in: Int J Cardiol. 2018;263:187.
Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45:458-465.
Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs. 2015;29:101-111.
Kikuchi YS, Sato W, Ataka K, Yagisawa K, Omori Y, Kanbayashi T, Shimizu T. Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1973-1978.
Grover S, Hazari N, Chakrabarti S, Avasthi A. Association of clozapine with seizures: a brief report involving 222 patients prescribed clozapine. East Asian Archives of Psychiatry. 2015;25:73-78.
Yadav DS. Clozapine and seizure risk: primary or secondary prophylaxis? Progress in Neurology and Psychiatry. 2022;26:28-31.
Caetano D. Use of anticonvulsants as prophylaxis for seizures in patients on clozapine. Australas Psychiatry. 2014;22:78-83.
Hatano M, Yamada K, Matsuzaki H, Yokoi R, Saito T, Yamada S. Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database. PLoS One. 2023;18:e0287122.
Aydin M, Ilhan BC, Calisir S, Yildirim S, Eren I. Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports. Ther Adv Psychopharmacol. 2016;6:33-38.
Drew L. Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry. 2013;21:335-337.
Balda MV, Garay OU, Papale RM, Bignone I, Bologna VG, Brandolini A, et al. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). IInt Clin Psychopharmacol. 2015;30:109-114.
Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, Bird R, Siskind D. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138:101-109.
Verdoux H, Quiles C, de Leon J. Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations. Schizophr Res. 2024;268:233-242.
